Adicet Bio Inc (ACET)

Adicet Bio's stock price has experienced significant fluctuations in the past six months. As of November 21, 2025, the share price was $0.60, representing a decline of 33.08% from $0.90 on November 22, 2024. Key events impacting the stock include a strategic pipeline prioritization announced around August 2025, which involved halting the development of ADI-270 for clear cell renal cell carcinoma and implementing a 30% workforce reduction. In October 2025, Adicet Bio successfully completed a capital raise of $74.8 million, further extending its cash runway into the second half of 2027. More recently, in November 2025, the stock showed some positive momentum, with shares rising on several days, attributed to renewed market attention to small-cap biotech stocks and positive analyst sentiment.

As a clinical-stage biotechnology company, Adicet Bio, Inc. does not currently generate revenue from commercial product sales and therefore has no typical demand seasonality. Its financial performance is more sensitive to clinical data readouts, regulatory milestones, and funding rounds rather than seasonal consumer demand.

Adicet Bio, Inc. is a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Their approach involves engineering gamma delta T cells with CARs to target and eliminate diseased cells. The lead product candidate, ADI-001, is in Phase 1 clinical trials for autoimmune diseases and relapsed/refractory B-cell non-Hodgkin's lymphoma. The company is also advancing ADI-212 for solid tumors, with an investigational new drug application planned for the first quarter of 2026. The ADI-270 program has been discontinued as part of a strategic pipeline prioritization.

Adicet Bio, Inc. was initially established in Menlo Park, California, and has since expanded its operations to include a significant presence in Boston, Massachusetts, which now serves as its headquarters. The company primarily operates in the United States.

Adicet Bio's brand reputation, as reflected by analyst sentiment, appears to be cautiously optimistic with a consensus rating of "Moderate Buy" or "Strong Buy" from analysts. Analysts have highlighted the favorable positioning of its lead product candidate, ADI-001. However, the company faces a negative outlook due to projected net losses and risks associated with potential delays in clinical trials, negative clinical data, and regulatory setbacks.

Adicet Bio, Inc. has a diverse ownership structure, with institutional shareholders holding 33.50% of the stock, Adicet Bio insiders holding 10.89%, and retail investors holding 55.61%. Major institutional owners include Orbimed Advisors LLC, Tang Capital Management LLC, and Ra Capital Management LP. Jonathan Silverstein is the largest individual shareholder.